Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Clinically Significant Outcomes of Interest (2 of 2)
Long-term outcomes that were reported in studies and analyzed in the CER include pain control, clinical remission, quality of life (QoL), growth and development, and health status, as assessed with the Child Health Assessment Questionnaire (CHAQ), or by joint function, functional ability, and mortality.
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.